Abstract:Systemic lupus erythematosus (SLE) is a chronic and autoimmunity-mediated diffuse connective tissue disease. The mainstay of treatments for SLE mainly relies on corticosteroids and immunosuppressants, which have a series of unavoidable side effects. Therefore, it is of fundamental importance to search novel therapeutic targets for better treatment with favorable efficacy and minor side effects. Recent studies shed light on potential therapeutic targets for SLE, mainly covering the followings: B-cell/plasmocyte-related targets [B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), CD20, CD22, CD19/FcγRIIb, Bruton tyrosine kinase (Btk), and proteasome], T cell-related targets [calcineurin, mammalian target of rapamycin (mTOR), regulatory factor X1 (RFX1), and Rho kinase], macrophage-related targets (macrophage migration inhibitory factor), intracellular signaling molecules, cytokines (cereblon, histone deacetylase 6, Janus activated kinase/signal transducer and activator of transcription), co-stimulating factors (CD28/B7, CD40/CD154), IgE autoantibody, and gut microbiome. Among them, belimumab (a humanized monoclonal antibody against B-lymphocyte stimulator) and telitacicept (a recombinant human B-lymphocyte stimulator receptor-antibody fusion protein) have been sequentially approved for the clinical treatment of SLE in China. A variety of new targeted-therapy drugs are in the Phase 2 or Phase 3 clinical trials,among which anifrolumab (a human monoclonal antibody against type I interferon receptor subunit 1) has completed a Phase 3 clinical trial with good responses achieved, although its incidence of herpes zoster is higher than that in the control group. The research progress in both molecular mechanisms and new drug development for different therapeutic targets have greatly promoted our better and in-depth understanding of the pathogenesis of SLE, and have also reflected the complexity and heterogeneity of the disease. Successful development and clinical application of more novel therapies would no doubt usher in a new era of individualized treatment for SLE in the future.

Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

Immunological pathogenesis and treatment of systemic lupus erythematosus

JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Updates on Clinical Trials in Systemic Lupus Erythematosus

JAK Inhibitors: Prospects in Connective Tissue Diseases

Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions

Targeting interferons and their pathways in systemic lupus erythematosus

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

Advances in therapeutic targets-related study on systemic lupus erythematosus

Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

JAK inhibitor selectivity: new opportunities, better drugs?

Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

[Progress and perspectives in the treatment of systemic lupus erythematosus]

Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development

Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs